After recording its highest trading volume in a year last Friday, now seems like a good time to pay attention to Exousia Pro (OTC Pink: MAJI, formerly Marijuana Inc.). The company announced they filed for a name and ticker change with FINRA last week, following its acquisition of Exousia in January and an update to its share structure that reduced authorized shares from 750 million to 250 million. That deal secured exclusive rights to patented exosome technology, positioning the company in one of biotech’s fastest-growing sectors.
Exosomes are gaining traction as a next-generation drug delivery system, with the global market projected to grow from $178.2 million in 2022 to $2.21 billion by 2032. Unlike traditional treatments, exosomes can transport therapies directly into cells, increasing effectiveness and reducing side effects. Exousia holds exclusive global rights to a patented process that efficiently loads genetic material into exosomes, a key advantage in treating diseases like glioblastoma and Alzheimer’s. Early research has already shown that its technology can successfully cross the blood-brain barrier and improve drug delivery, making it a potential game-changer in the field.
Beyond therapeutics, Exousia is entering the commercial market with plant-based exosomes. According to its most recent investor presentation, the company expected to complete its first batch of plant-derived exosomes by February 2025, with product sales projected to begin in Q2. The exosome skincare industry alone is projected to double from $310 million in 2025 to $633 million by 2033 as demand for regenerative, anti-aging treatments grows, creating a lucrative niche for Exousia’s plant-based products.. Exousia has identified research institutions, biotech firms, and universities as key target markets for its plant-derived exosome products, presenting an early revenue opportunity.
A clear sign of growing momentum in the exosome space is the attention from major pharmaceutical companies. In June 2020, Eli Lilly partnered with Evox Therapeutics to develop RNAi and antisense oligonucleotides for neurological disorders using Evox's exosome technology. In November 2021, Lonza further solidified its position by acquiring Codiak BioSciences' exosome manufacturing facility in Lexington, Massachusetts, securing global rights to its cGMP production process.
Now, as the industry accelerates, Exousia Pro is positioning itself at the forefront. With its name and ticker change in progress, commercial production approaching, and a foothold in an industry seeing explosive growth, the company is entering its next phase at a time when biotech innovation is drawing more attention than ever.
Disclaimer: The content provided is for informational purposes only and does not constitute a comprehensive analysis of the mentioned topics. All views, opinions, and predictions are those of the author at the time of writing and may change. This should not be considered as investment advice or a solicitation to buy or sell any securities. Readers are strongly advised to review the company’s official disclosures, filings, and updates to ensure accurate and current information. Always conduct your own research or consult with a financial advisor before making investment decisions. The author and publisher are not liable for any losses or damages arising from the use of this information. Please remember that all investments carry risks, including potential loss of principal.